Scancell Holdings PLC

Company Profile

• Business description

  Scancell Holdings PLC is a clinical-stage biotechnology company developing treatments for unmet needs in cancer. The Company leverages its ImmunoBody and Moditope platforms to develop targeted, off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent, and long-lasting tumour-specific immunity. Its product, iSCIB1+, is an ImmunoBody DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. The ImmunoBody platform uses DNA-encoded modified antibodies engineered to express epitopes from cancer antigens and target activated antigen-presenting cells in vivo. iSCIB1+ is developed for the treatment of melanoma with checkpoint inhibitors and is administered by needle-free intramuscular injection.

• Contact

  Sanders Road
  Unit 202, Bellhouse Building
  Oxford Science Park
  OxfordOX4 4GD
  GBR

  T: +44 1865582066

  https://www.scancell.co.uk

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  30 April 2027

  Employees

  61